Design and baseline characteristics of an observational study in Japanese patients with hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH).

What Was Tested

The paper reports a study of Losartan, published as a clinical trial.

The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicenter observational study that was designed to enroll hypertensive Japanese patients (>30,000 subjects).

The patients in this study received treatment with open-label losartan, an angiotensin II receptor antagonist, for a maximum of 5 years.

Who Took Part

The study group was 30,000 subjects.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as open-label and multicenter.

Everyone knew when Losartan was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the subjects came from several places.

What Was Measured

The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicenter observational study that was designed to enroll hypertensive Japanese patients (>30,000 subjects).

PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Asian People, Blood Pressure Monitoring, Ambulatory, Hypertension, Japan and Losartan.

What This Means in Plain Language

The paper is an open-label and multicenter study of Losartan in 30,000 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2007 (Hypertension research : official journal of the Japanese Society of Hypertension), a journal based in England.

More context: all human trials.